CDXSCodexisCDXS info
$5.28info3.13%24h
Global rank13450
Market cap$368.70M
Change 7d-4.00%
YTD Performance76.59%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Codexis (CDXS) Stock Overview

    Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with NestlΓ© Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

    CDXS Stock Information

    Symbol
    CDXS
    Address
    200 Penobscot DriveRedwood City, CA 94063United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://www.codexis.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    650 421 8100

    Codexis (CDXS) Price Chart

    -
    Value:-

    Codexis Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $5.28
    N/A
    Market Cap
    $368.70M
    N/A
    Shares Outstanding
    69.83M
    N/A
    Employees
    248.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org